Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients.
This Austrian real-world study examined afamelanotide treatment outcomes in 20 patients with erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe phototoxic reactions upon light exposure. Researchers compared pre- and post-treatment data on quality of life (QoL), phototoxic burn tolerance time (PBTT), UV index, and the incidence and severity of phototoxic reactions for the year 2023. The study found that the EPP-specific QoL score increased markedly, with the median rising from 11.11 to 79.17 under therapy. PBTT also improved substantially, increasing from a median of 15 minutes before treatment to 250 minutes during treatment. The proportion of patients experiencing phototoxic reactions fell from 88% at baseline to 33% on therapy. Reported side effects were described as only mild and transient. The authors concluded that these findings support the effectiveness and safety of afamelanotide in EPP. Limitations include the small sample size (n=20), the non-randomized, uncontrolled observational design, and the potential for recall or reporting bias inherent to real-world cohort studies.
Why this grade: While conducted in human patients, the study is a small (n=20), uncontrolled, single-country observational cohort without a comparator arm, limiting causal inference.
Background Erythropoietic protoporphyria (EPP) is a rare genetic disorder characterized by severe phototoxic reactions that occur within minutes of light exposure. In clinical studies, afamelanotide has been shown to prolong pain-free sun exposure, improve quality of life, and reduce the frequency and severity of phototoxic reactions. Objective To present the real-world data of the Austrian EPP cohort treated with afamelanotide. Patients and methods Data from all Austrian EPP patients treated with afamelanotide in 2023 (n = 20) were analyzed and compared to baseline data on quality of life, phototoxic burn tolerance time (PBTT), reported UV index on the day with the longest PBTT, and incidence and severity of phototoxic reactions. Results Before treatment, the EPP QoL score had a median of 11.11 (IQR 3.03-19.44) and increased to a median of 79.17 (IQR 75.00-97.22) under therapy. Phototoxic burn tolerance time (PBTT) increased from a median of 15 minutes (IQR 10-25) to a median of 250 minutes (IQR 120-300) under therapy. Before therapy 88% of patients had phototoxic reactions, while on therapy only 33% were affected. Treatment side effects were only mild and transient. Conclusions The real-world data of the Austrian cohort confirm the effectiveness and safety of afamelanotide in EPP patients.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.